Compare SEER & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEER | GANX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 78.2M |
| IPO Year | 2020 | 2021 |
| Metric | SEER | GANX |
|---|---|---|
| Price | $1.79 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 364.2K | ★ 507.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.40 | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,578,000.00 | $55,180.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $25.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.65 | $1.41 |
| 52 Week High | $2.41 | $4.34 |
| Indicator | SEER | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 46.62 |
| Support Level | $1.76 | $1.73 |
| Resistance Level | $1.84 | $2.09 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 32.26 | 62.50 |
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.